BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 26184556)

  • 1. Chronic baseline prostate inflammation is associated with lower tumor volume in men with prostate cancer on repeat biopsy: Results from the REDUCE study.
    Moreira DM; Nickel JC; Andriole GL; Castro-Santamaria R; Freedland SJ
    Prostate; 2015 Sep; 75(13):1492-8. PubMed ID: 26184556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study.
    Moreira DM; Nickel JC; Gerber L; Muller RL; Andriole GL; Castro-Santamaria R; Freedland SJ
    Cancer; 2014 Jan; 120(2):190-6. PubMed ID: 24323568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline prostate atrophy is associated with lower tumor volume in men with prostate cancer on repeat biopsy.
    Moreira DM; Andriole GL; Castro-Santamaria R; Freedland SJ
    Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):106-112. PubMed ID: 29203895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline Prostate Atrophy is Associated with Reduced Risk of Prostate Cancer in Men Undergoing Repeat Prostate Biopsy.
    Moreira DM; Bostwick DG; Andriole GL; Peterson BL; Cohen HJ; Castro-Santamaria R; Freedland SJ
    J Urol; 2015 Nov; 194(5):1241-6. PubMed ID: 26165588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Greater extent of prostate inflammation in negative biopsies is associated with lower risk of prostate cancer on repeat biopsy: results from the REDUCE study.
    Moreira DM; Nickel JC; Andriole GL; Castro-Santamaria R; Freedland SJ
    Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):180-4. PubMed ID: 26782712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.
    Marberger M; Freedland SJ; Andriole GL; Emberton M; Pettaway C; Montorsi F; Teloken C; Rittmaster RS; Somerville MC; Castro R
    BJU Int; 2012 Apr; 109(8):1162-9. PubMed ID: 21699645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic Baseline Prostate Inflammation is Associated with Lower Tumor Grade in Men with Prostate Cancer on Repeat Biopsy: Results from the REDUCE Study.
    Naha U; Nickel JC; Andriole GL; Freedland SJ; Moreira DM
    J Urol; 2021 Mar; 205(3):755-760. PubMed ID: 33080149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline Basal Cell Hyperplasia Is not Associated With Baseline Lower Urinary Tract Symptoms, Baseline Clinical Prostatitis or Prostate Cancer in Repeat Biopsies.
    Freitas D; Andriole GL; Freedland SJ; Neto BS; Moreira DM
    Urology; 2019 Jul; 129():160-164. PubMed ID: 30914334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial.
    Aubin SM; Reid J; Sarno MJ; Blase A; Aussie J; Rittenhouse H; Rittmaster RS; Andriole GL; Groskopf J
    Urology; 2011 Aug; 78(2):380-5. PubMed ID: 21820580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial.
    Nickel JC; Roehrborn CG; O'leary MP; Bostwick DG; Somerville MC; Rittmaster RS
    J Urol; 2007 Sep; 178(3 Pt 1):896-900; discussion 900-1. PubMed ID: 17632164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy?
    Tombal B; Andriole GL; de la Taille A; Gontero P; Haese A; Remzi M; Speakman M; Smets L; Stoevelaar H
    Urology; 2013 May; 81(5):998-1004. PubMed ID: 23523291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study.
    Margel D; Nandy I; Wilson TH; Castro R; Fleshner N
    J Urol; 2013 Dec; 190(6):2039-45. PubMed ID: 23820059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obesity is associated with increased prostate growth and attenuated prostate volume reduction by dutasteride.
    Muller RL; Gerber L; Moreira DM; Andriole G; Hamilton RJ; Fleshner N; Parsons JK; Freedland SJ
    Eur Urol; 2013 Jun; 63(6):1115-21. PubMed ID: 23541458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.
    Andriole GL; Bostwick D; Brawley OW; Gomella L; Marberger M; Montorsi F; Pettaway C; Tammela TL; Teloken C; Tindall D; Freedland SJ; Somerville MC; Wilson TH; Fowler I; Castro R; Rittmaster RS;
    J Urol; 2011 Jan; 185(1):126-31. PubMed ID: 21074214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dutasteride reduces prostatitis symptoms compared with placebo in men enrolled in the REDUCE study.
    Nickel JC; Roehrborn C; Montorsi F; Wilson TH; Rittmaster RS
    J Urol; 2011 Oct; 186(4):1313-8. PubMed ID: 21849186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The REDUCE Follow-Up Study: low rate of new prostate cancer diagnoses observed during a 2-year, observational, followup study of men who participated in the REDUCE trial.
    Grubb RL; Andriole GL; Somerville MC; Mahoney C; Manyak MJ; Castro R
    J Urol; 2013 Mar; 189(3):871-7. PubMed ID: 23021996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Both acute and chronic inflammation are associated with less perineural invasion in men with prostate cancer on repeat biopsy.
    Kuang AG; Nickel JC; Andriole GL; Castro-Santamaria R; Freedland SJ; Moreira DM
    BJU Int; 2019 Jan; 123(1):91-97. PubMed ID: 29873889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate volume index and prostatic chronic inflammation predicted low tumor load in 945 patients at baseline prostate biopsy.
    Porcaro AB; Tafuri A; Sebben M; Novella G; Processali T; Pirozzi M; Amigoni N; Rizzetto R; Shakir A; Mariotto A; Brunelli M; Cerruto MA; Cacciamani GE; Migliorini F; Siracusano S; Artibani W
    World J Urol; 2020 Apr; 38(4):957-964. PubMed ID: 31154465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen increase during dutasteride to indicate the need for prostate biopsy: influence of prostatic inflammation.
    Sciarra A; Maggi M; Fasulo A; Salciccia S; Gentile V; Cattarino S; Gentilucci A
    Urologia; 2017 Aug; 84(3):158-164. PubMed ID: 28430341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extent of Baseline Prostate Atrophy Is Associated With Lower Incidence of Low- and High-grade Prostate Cancer on Repeat Biopsy.
    Freitas DM; Andriole GL; Castro-Santamaria R; Freedland SJ; Moreira DM
    Urology; 2017 May; 103():161-166. PubMed ID: 28024967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.